|
EQS-News: Medios AG / Key word(s): Research Update Hauck & Aufhäuser starts coverage of Medios AG with buy recommendation and price target of €23.00 07.06.2024 / 10:28 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release Hauck & Aufhäuser starts coverage of Medios AG with buy recommendation and price target of €23.00 Berlin, June 7, 2024 – Hauck & Aufhäuser Investment Banking initiated coverage of Medios AG yesterday and recommended the shares as a “buy”. The price target is €23.00 and thus around 55 percent above the Xetra closing price on June 5, 2024 (€14.86). In addition to Hauck & Aufhäuser, Medios AG continues to be covered by Berenberg, Bryan, Garnier & Co, Deutsche Bank, Jefferies, Kepler Cheuvreux, Metzler Capital Markets and Warburg. ——————- About Medios AG Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies. Medios AG is Germany’s first listed specialty pharmaceutical company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard). Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Medios AG Heidestraße 9 | 10557 Berlin T +49 30 232 566 800 Disclaimer This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. 07.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Fianlimab by Regeneron Pharmaceuticals for Lymphoma: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes
June 18, 2024